Education:

• Undergraduate: Toyama Medical and Pharmaceutical University, Japan, MD, 1997.
• Residencies: Department of Urology, Hamamatsu University School of Medicine Hospital, Japan, 1997-1999, 2006; Seirei Hamamatsu General Hospital, Japan, 2004-2006

Current Research:

I’m researching Dmp1 (cyclin D binding myb-like protein 1), a haplo-insufficient tumor suppressor gene, in Dr. Kazushi Inoue's lab. My current interest is how Dmp1 disruption affects the fashion of human cancers, especially human non-small-cell lung cancer.  Dmp1 is a transcription factor that causes p19Arf-, p53-dependent cell cycle arrest in primary cells and Dmp1-/- and Dmp1+/- mice are prone to tumor development, especially lung adenocarcinoma. Previous data showed that the Dmp1 promoter is activated by Ras-Raf-MEK-ERK pathway and activation of the p19Arf by oncogenic Ras is dependent on Dmp1. On the other hand, the Dmp1 promoter is inhibited by E2F signaling and by genotoxic stimuli mediated by NF-kB.  Our laboratory recently showed that the human DMP1 gene is deleted around 40% of human non-small cell lung carcinomas, and the deletion was mutually exclusive from those of INK4a/ARF and/ or the p53 loci.

Figure 1: The pattern of LOH for hDMP1 in lung cancer.  Genomic DNA was extracted from lung cancer with normal counterpart.  The nucleotide repeats were amplified by PCR with labeled primer and the area peaks were quantitated (Ref: Mallakin et al. Cancer Cell 2007 Oct 12(4):381-94.)

Publications:

Sugiyama T, Taneja P, Frazier DP, Kendig RD, Morgan RL, Matise LA, Lagedrost SJ, Inoue K. Oncogenic and non-oncogenic signaling pathways that regulate Dmp1 (Dmtf1) (review). Clinical Medicine: Oncology 2008; 2: 209-19.

Inoue K, Sugiyama T, Taneja P, Morgan RL, Frazier DP.  Emerging roles of DMP1 in lung cancer (review).  Cancer Res 2008 Jun 15; 68(12):4487-90.

Sugiyama T, Frazier DP, Taneja P, Morgan RL, Willingham MC,  Inoue K.  The role of Dmp1 and its future in lung cancer diagnostics (review).  Expert Rev Mol Diagn 2008 8(4), 435-447

Taneja P, Frazier DP, Sugiyama T, Lagedrost S, Inoue K. Control of cellular physiology by transcription factors E2F and their roles in carcinogenesis (review).  Research Signpost 2008: 179-197.

Mallakin A, Sugiyama T, Taneja P, Matise LA, Frazier DP, Choudhary M, Hawkins GA, D'Agostino RB Jr, Willingham MC, Inoue K. Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell. 2007 Oct; 12(4):381-94.

Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, Sugiyama T, Takayama T, Mugiya S, Ozono S, and Nozawa R. Evaluation of S100A10, ANNEXIN II and B-FABP expression as a marker for patients with renal cell carcinoma. Cancer Sci 98 77-82, 2007

Sugiyama T, Mugiya S, Takayama T, Kai F, Kudo S, Ozono S. Preoperative serum Immunosuppressive acidic protein in patients with renal cell carcinoma. [Article in Japanese] Japanese Journal of Urological Surgery 2006.

Takayama T, Mugiya S, Sugiyama T, Aoki T, Furuse H, Liu H, Hirano Y, Kai F, Ushiyama T and Ozono S. High levels of thymidine phosphorylase as an independent prognostic factor in renal cell carcinoma. Jpn J Clin Oncol. 36:564-569, 2006.

Professional Memberships:

• American Association for Cancer Research (Associate member)
• Japanese Cancer Association
• The Japanese Urological Association
• The Japanese Society for Dialysis Therapy